<DOC>
	<DOCNO>NCT00064402</DOCNO>
	<brief_summary>The purpose study assess bronchodilator effect safety multiple daily dos arformoterol administer 12 week maintenance treatment patient COPD</brief_summary>
	<brief_title>Determine Safety Efficacy ( R , R ) -Formoterol Treatment Subjects With COPD</brief_title>
	<detailed_description>This double-blind , double-dummy , randomize , placebo- active-controlled , multicenter , parallel-group study adult subject COPD . The study double blind use unit dose vial ( UDV ) metered-dose inhaler ( MDI ) placebo , appropriate . The primary efficacy analysis utilized placebo control . Secondary analysis primary efficacy endpoint utilized active control , include comparison placebo active control . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Be willing comply study procedure visit schedule Are least 35 year age Female subject &gt; 65 year age must serum pregnancy test conduct Visit 1 confirm negative prior randomization Subjects childbearing potential must use acceptable method birth control . Female subject consider childbearing potential must : document surgically sterile , OR postmenopausal . Have primary diagnosis COPD . Diagnosis make screen process . Have minimum smoking history 15 packyears ( packyears = number cigarette pack per day time number year ) . Have chest xray consistent diagnosis COPD take &lt; 3 month prior study start Able complete study questionnaire log reliably Female subject pregnant lactating Have participate investigational drug study within 30 day prior study start , currently participate another investigational drug study Subject whose schedule travel prevents completion require visit Are schedule inpatient hospitalization , include elective surgery trial Have lifethreatening/unstable respiratory status , include upper low respiratory tract infection , within previous 30 day History asthma chronic respiratory disease COPD ( chronic bronchitis and/or emphysema ) Have clinically significant cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol Have history cancer except nonmelanomatous skin cancer Have history lung resection one full lobe Requires continuous supplemental oxygen therapy . Has change dose type medication COPD within 14 day prior screen visit Have know sensitivity arformoterol , ipratropium , salmeterol albuterol excipients contain formulation Have history substance abuse drug abuse within 12 month , positive urine drug screen Are use prescription drug concomitant betaagonist administration contraindicate ( e.g. , betablockers )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>